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Commentary
Assuring Access to Data for Chemical Evaluations
Lynn R. Goldman1 and Ellen K. Silbergeld 2
1School

of Public Health and Health Services, The George Washington University, Washington, DC, USA; 2Department of Environmental
Health Sciences, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA

Background: A database for studies used for U.S. Environmental Protection Agency (EPA)
pesticide and chemical reviews would be an excellent resource for increasing transparency and
improving systematic assessments of pesticides and chemicals. There is increased demand for
disclosure of raw data from studies used by the U.S. EPA in these reviews.
oBjectives: Because the Information Quality Act (IQA) of 2001 provides an avenue for request
of raw data, we reviewed all IQA requests to the U.S. EPA in 2002–2012 and the U.S. EPA’s
responses. We identified other mechanisms to access such data: public access databases, the Freedom
of Information Act (FOIA), and reanalysis by a third party.
discussion: Only two IQA requests to the U.S. EPA were for raw data. Both of these were fulfilled
under FOIA, not the IQA. Barriers to the U.S. EPA’s proactive collection of all such data include
costs to the U.S. EPA and researchers, significant time burdens for researchers, and major regulatory
delays. The U.S. EPA regulatory authority in this area is weak, especially for research conducted in
the past, not funded by the U.S. government, and/or conducted abroad. The U.S. EPA is also
constrained by industry confidential business information (CBI) claims for regulatory testing data
under U.S. chemical and pesticide laws. The National Institutes of Health Clinical Trials database
systematically collects statistical data about clinical trials but not raw data; this database may be a
model for data from studies of chemicals and pesticides.
conclusions: A database that registers studies and obtains systematic sets of parameters and results
would be more feasible than a system that attempts to make all raw data available proactively. Such
a proposal would not obviate rights under the IQA to obtain raw data at a later point.
key words: access to information; chemicals, hazardous; pesticides; review, systematic. Environ
Health Perspect 121:149–152 (2013). http://dx.doi.org/10.1289/ehp.1206101 [Online
11 December 2012]

The U.S. Environmental Protection Agency
(EPA) is one among many agencies covered
by the Information Quality Act (IQA 2001),
an amendment to the Treasury and General
Government Appropriations Act for fiscal year
2001 that has been viewed as a mechanism to
increase access to such information and to seek
corrections if parties think that government
agencies have used faulty information and
analyses. The Office of Management and
Budget (OMB) issued IQA guidelines that
apply to all agencies in the Executive Branch:
When these agencies provide “influential scien
tific, financial, or statistical information,” they
also “shall include a high degree of transparency
about data and methods to facilitate the repro
ducibility of such information by qualified
third parties” (OMB 2002). The law was
enacted without debate or hearing. In the
absence of an extensive legislative history and
because both the IQA and OMB guidelines
were silent about whether agency responses
were judicially reviewable, some had viewed
the act as providing a new avenue for legal
challenges of agency decisions across the U.S.
government. For example, in 2006 the U.S.
Fourth Circuit Court of Appeals ruled that
plaintiffs did not have standing to sue the
Department of Health and Human Services
under Title III of the IQA to compel access
to a study conducted by the National Heart,
Lung, and Blood Institute (NHLBI) that
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was used to support action by the Food and
Drug Administration (FDA) on dietary salt
(Salt Institute v. Leavitt 2006). A number of
industry groups had petitioned the NHLBI to
make the raw data from the study available so
that they could do subgroup reanalyses. The
court found that the plaintiffs had received no
injury from being denied access to the NHLBI
data and thus did not have standing. However,
the court also noted that the petitioners had a
longstanding right to request the raw data from
the study using the Freedom of Information
Act (FOIA 1966). In its response, the NHLBI
noted that it was preparing a public access data
set for release, which it later made available
(NHLBI 2005). Although this case was
resolved under existing FOIA mechanisms,
in the wake of this litigation there has been
concern that the IQA does not provide outside
parties sufficient access to the data for studies
that underlie regulatory decisions made by
U.S. government agencies. There is increasing
interest in improving the methods by which
chemical and pesticide hazards and risks are
evaluated not only by government but also
by independent scientists (Bucher et al. 2011;
Woodruff et al. 2011). This interest has
spurred increased demand for transparency and
disclosure of the data used by the U.S. EPA
to make evaluations that support regulatory
decisions for chemicals and pesticides. In this
context, we examine the role of the IQA in
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making such data more accessible and suggest
alternative approaches.

Review of Requests for Data
To find out how responsive the U.S. EPA
has been to requests for raw data under the
IQA, we reviewed 79 requests filed with the
U.S. EPA between 2002 and 2012 either
to correct or to reconsider the data that the
U.S. EPA used in evaluations supporting its
regulatory decisions during that period. Under
OMB guidance for the IQA (OMB 2002),
parties can request that agencies reconsider
or correct any information used to support
regulatory decisions; usually these requests
are made in the form of letters. The U.S. EPA
posted these 79 requests on its web site,
according to OMB guidelines (U.S. EPA
2012a). Interestingly, only two of these
requested raw data.
The first request for raw data was filed
in December 2003 by the Perchlorate Study
Group, an industry consortium of manu
facturers and users of perchlorate (Aerojet,
American Pacific Corporation, Kerr-McGee
Chemical, and Lockheed Martin). They
requested that the U.S. EPA provide raw data
from experimental studies (Girard 2003). The
U.S. EPA granted this request in September
2004 and provided access to brain images and
contractor’s reports (Gilman 2003).
The second case was filed by the Association
of Battery Recyclers (ABR) in October 2008
(Steinwurtzel 2008). Now called America’s
Battery Recyclers, and formerly called the
Secondary Lead Smelters Association, the
ABR is a group of auto and industrial battery
recyclers, primary lead producers, and users
of recycled lead (America’s Battery Recyclers
2012). The ABR requested raw data from a
study of lead toxicity (Lanphear et al. 2005)
that was among several published studies relied
upon by the U.S. EPA in its development of
the National Ambient Air Quality Standard
(NAAQS) for lead under the Clean Air Act
Amendments (1990). Because the ABR and
others had taken the U.S. EPA to court to
overturn the lead NAAQ rule at the same
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time, the U.S. EPA opted to postpone consid
eration of the request under the IQA pending
the decision of the court. In its response to
the request, the U.S. EPA noted that con
cerns about the data analysis had been noted
in comments during the rule-making process
and that the U.S. EPA had commissioned new
external peer reviews of the study (U.S. EPA
2012a) in addition to a reanalysis of the data of
Lanphear et al. (Rothenberg and Rothenberg
2005). After the lead NAAQS was upheld
in July 2010, the ABR again requested that
the U.S. EPA provide access to the Lanphear
data (Steinwurtzel 2010). Meanwhile, litiga
tion was filed over the delay in providing the
data. This litigation was dropped when the
U.S. EPA FOIA office worked out an agree
ment with the Cincinnati Children’s Medical
Center to obtain the Lanphear study data
(Lanphear BP, personal communication; Pohl
v. U.S. EPA et al. 2012). U.S. EPA attor
neys determined that access to the data was
required under the 1998 Shelby Amendment,
which makes federally funded research data
accessible to the public under FOIA (Treasury
and General Government Appropriations
Appropriations Act 1998). Thus, as for the
request to the NHLBI to provide data con
cerning the salt study (Salt Institute v. Leavitt
2006), the resolution of the request was man
aged under FOIA.
Because requests for raw data are few
and far between, it has not been onerous for
the U.S. EPA to provide such data. Existing
mechanisms have provided the ability to reana
lyze data by a) development and availability of
a public-access database (with suitable protec
tions for the human subjects involved in such
studies); b) provision of raw data via FOIA, for
cases in which data are in possession of or can
be obtained by the agency (e.g., the perchlorate
case cited above); and c) reanalysis of data by a
third party. As an example of the third mecha
nism, the widely publicized results from the
Harvard Six Cities Study (Dockery et al. 1993)
were used by the U.S. EPA in 1997 as a basis
for developing new standards for fine particu
late matter (≤ 2.5 µm in aerodynamic diam
eter) air pollution (U.S. EPA 1997). Interested
parties, mostly from industry, raised questions
about study analysis and interpretation. The
raw data were not in the possession of the
U.S. EPA, and the U.S. EPA could not compel
the submission of these data from Harvard
University or the funding source, the American
Cancer Society. Under pressure from govern
ment agencies and industry, Harvard and the
American Cancer Society voluntarily requested
that the Health Effects Institute (HEI) step in
as a third party to supervise a reanalysis of their
data. The HEI [a consortium of industry, aca
demic, and government scientists established
by the Clean Air Act Amendments (1990)]
provided the data for reanalysis by a third party
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selected by a science advisory committee that
included representation from interested parties
who had argued for an independent reanalysis,
thus providing a process to address the uncer
tainties about the analysis and interpretation
(HEI 2000).

Discussion
Over time, the U.S. EPA has come to rely
increasingly on a large number of scien
tific studies to complete reviews for a single
chemical. This is illustrated by the case of
2,3,7,8‑TCDD (2,3,7,8-tetrachlorodibenzop-dioxin). In its recent assessment of TCDD,
the U.S. EPA identified some 2,000 studies
directly relevant to its review of dioxin toxicity.
From these, the U.S. EPA selected 10 “key”
epidemiologic studies and 74 “key” experi
mental animal studies. Even for this smaller
subset of “key” studies, the raw data for each
human study and animal experiment are sub
stantial, and most of the data on TCDD were
not in the possession of the U.S. EPA (2012b).
There are several mechanisms through
which the U.S. EPA might obtain these data.
The U.S. EPA could require that investiga
tors submit their raw data to the agency upon
completion of their research as a condition
of U.S. EPA funding, but this would not
completely solve the problem. Most research
evaluated by the U.S. EPA for regulatory deci
sion making is not funded by the U.S. EPA.
In these cases, the U.S. EPA would have to
undertake an extensive collection of raw data
from study investigators, which would be
costly to the U.S. EPA and burdensome to
the research community. Not insignificantly,
this would create major delays in rule mak
ing. In terms of resource allocation, it is rea
sonable to ask how much of the U.S. EPA’s
budget could be allocated to accomplish this,
and where this would rank relative to other
priorities, such as increasing the numbers of
priority assessments to meet the U.S. EPA’s
statutory goals.
In addition to the burden on the U.S. EPA,
there would be a significant burden on the
scientific community that produces most of
the relevant research, and it is very likely that
there would be significant pushback from the
academic community under the Paperwork
Reduction Act (1995). In fact, the Paperwork
Reduction Act, which was enacted to reduce
the total amount of paperwork handled by
the U.S. government, would not allow the
U.S. EPA to undertake such a massive data
collection without establishing that the bur
den imposed upon the research community
would be justified by the benefits of providing
the data.
At the least, scientists would need funding
to respond to requests that are generated as
a consequence of the use of their studies by
the U.S. EPA rather than any action taken
volume

by the investigators themselves. Burdened by
other responsibilities and unable to fund such
activities from grants provided by sources
other than the U.S. EPA, scientists are not
likely to voluntarily provide the U.S. EPA
with raw data from studies conducted months
to decades in the past simply because the
U.S. EPA has decided to include those studies
in their latest assessment.
Moreover, the U.S. EPA would not have
clear legal authority to compel the submis
sion of data from industry, federally funded
studies conducted prior to the 1998 Shelby
Amendment, studies funded by other federal
agencies, or studies that are not funded by
the U.S. government, including studies from
non-U.S. investigators. We therefore con
clude that a regulatory approach, in which
the U.S. EPA compels the submission of raw
data for all studies reviewed for rule making
on pesticides and chemicals, would not be
tenable. It could in fact have a chilling effect
on the engagement of the global scientific
community in research relevant to the protec
tion of human health and the environment.
Certainly, this is not in the best interests of
science-based policy.
In addition, there are other feasibility
issues. In the case of older studies, raw data
may not exist or may be difficult to access
because of storage on outdated media such as
tapes. For epidemiologic studies, considera
tion would need to be given to ethical issues
governing studies of human subjects. These
include protection of confidentiality and pri
vacy, and prevention of abuse of the data, for
example, by marketing companies who may
wish to identify patients with particular medi
cal conditions. Clinical-trials investigators have
been working for years to develop ways to
disclose data from human studies, including
mechanisms for placing data behind a bar
rier to universal access, so that it is accessible
only to those who meet conditions of use. In
the case of clinical trials, there are studies in
which removal of all identifying data negates
its scientific value; therefore access to the data
would need to be limited to protect privacy
(Hrynaszkiewicz et al. 2010). With adequate
resources and planning, these obstacles could
be anticipated and/or overcome.
In the case of research data concerning
chemicals and pesticides, the U.S. EPA also
is constrained by legal constructs that have
defined regulatory testing of pesticides as
“confidential business information” (CBI)
and that require the U.S. EPA to redact cer
tain data and obtain affirmations from recipi
ents that they will not give the remaining
data to multinational companies that might
seek to register the pesticide to market it in
other countries (U.S. EPA Office of Pesticide
Programs 2010). The U.S. EPA could improve
the web access to summaries and analyses of
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these data, which are publically available but
often difficult to find in web searches. This
would not be the same as providing access
to raw data. We therefore suggest that, in
the short run, industry should work with the
U.S. EPA to identify approaches to provide
more robust data sets for studies that they
submit to the U.S. EPA. The U.S. EPA also
could invite companies to voluntarily waive
CBI claims on tests of pesticides and chemi
cals. In the long run, we think that Congress
should amend the Toxic Substances Control
Act (1976) and the Federal Insecticide,
Fungicide, and Rodenticide Act (1972) as
amended by the Food Quality Protection Act
(1996) to ease CBI protections from pesticide
and chemical test data.
In an ideal world we would always favor
more disclosure over less, but it is not clear
how this should be done, or who should pay
for it. The HEI, which has an independent
governing board and is supported by a con
sortium of funders including the U.S. EPA
and the automobile and petrochemical indus
tries, may be a useful precedent. The HEI
requires that data from all HEI-funded studies
be made available as expeditiously as possible,
[taking] into consideration the legitimate intel
lectual interests of the investigator to have the
opportunity to benefit from his or her intellectual
endeavors and to publish subsequent analyses from
the data set (including additional analyses funded
by HEI). (HEI 2010)

The HEI attempts to balance the interests
of investigators with those of interested par
ties in cases of “studies of particularly high
regulatory importance being used to inform
decisions over a short time frame,” and
encourages its principal investigators to share
the data except in situations where “providing
the data would place an undue burden on the
investigator” (HEI 2010). For example, in
cases when there have been so many requests
that it was difficult for the investigators to
continue their research, the HEI has assisted
investigators with data sharing. In addition,
the HEI requires that data requesters pro
vide “reasonable reimbursement for both the
direct costs of providing the data, and for the
time of the investigator and/or HEI staff to
gather, transmit, and explicate the data” (HEI
2010). HEI also “will consider requests from
the investigator for a reasonable budget of
data archiving funds, to be provided as part
of the project budget” (HEI 2010). From
this precedent, it seems that proponents of
increased access to raw data need to consider
not only financial and time burdens on inves
tigators, but also a way to reasonably balance
the need for data access with the ability of
investigators to realize the fruits of their own
intellectual endeavors.
Another useful precedent that could serve
as a model for data sharing is the National
Environmental Health Perspectives •
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Institutes of Health (NIH) clinical trials
database (ClinicalTrials.gov; NIH 2012). It
does not contain “raw data” but rather con
tains detailed and useful information about
clinical-trial study designs and statistics that not
only convey results in a standardized fashion
but also identify important quality parameters
(e.g., drop‑out rates). Required by law (Section
113 of the Food and Drug Administration
Modernization Act 1997), the clinical trials
database was developed by the NIH with input
from the FDA and the National Library of
Medicine (NLM). Currently, many medi
cal journals require that trials be registered in
ClinicalTrials.gov prior to their publication;
as of 3 December 2012, 136,605 studies in
182 countries were registered. Although many
researchers are now are calling for access to raw
data for all clinical trials (Gotzsche 2011), the
ClinicalTrials.gov database has greatly increased
access to information about drug efficacy trials
and drug safety, and the development of such a
database for studies of chemicals and pesticides
would be a major step toward increasing the
transparency of the U.S. EPA’s evaluations and
making data more accessible to third parties.

Conclusions
At present, there does not seem to be a large
demand for raw data related to U.S. EPA
decision making; however, this may change
as formal evidentiary reviews of environ
mental health research become increasingly
common (Maull et al. 2012). Compared with
clinical trials, the acquisition of raw data for
chemicals and pesticides would be much more
complex, in part because it would require a
framework that can accommodate data from
numerous types of studies: observational and
experimental, animal, human, in vitro, and
high throughput screening studies.
For human epidemiologic studies, clear
and complete documentation would need to
be provided for interpretation of the variables
collected in such studies. This is no simple task
given, for example, a) the wide range of pos
sible study designs and the intricacies of design
of questionnaires and subsequent coding and
transformation of variables; b) environmental
and biomarker sample-collection procedures,
chain-of-custody and sample processing and
storage, laboratory analyses, data analysis, and
coding; and c) imputation of missing vari
ables or laboratory nondetects. Although it is
a standard practice to carefully document all
of these details, there is currently no gener
ally agreed-on manner in which to upload
such data into an electronic database. There
is a risk that people who were not involved in
data collection can misunderstand these details
and thus obtain erroneous results. Some effort
would be required to develop a standardized
system for reporting this kind of information.
For experimental animal studies, there should
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be parameters related to quality assessment
(e.g., blinding of investigators, randomization,
housing and care of animals).
If the U.S. EPA chose this path, the first
step might be to develop a framework simi
lar to ClinicalTrials.gov that would capture
statistics and other parameters but would not
necessarily require uploading raw data. With
adequate funding, involvement of the NLM
might provide more sophisticated informat
ics expertise to make the data more usable,
and the NLM or the National Toxicology
Program (NTP) could perhaps provide a
“home” for the data. The U.S. EPA and other
environmental agencies could also require (or
request) that investigators register their studies
with the database, and journals could require
registration as a condition of publication (as
some journals currently do for results of clini
cal trials) or suggest that it be done. Given
resource limitations, especially for investigators
in developing countries, this step might be
difficult for many investigators compared with
researchers who perform clinical trials.
A system that provides raw data might
be possible if the U.S. EPA could pilot the
development of a system that could handle
raw data using data already in its possession
[e.g., results of its intramural research, results
of U.S. EPA-funded extramural research
(where available), and any raw data that it
has requested from investigators in support
of risk-assessment activities]. Other federal
agencies, such as the NTP and the National
Institute for Occupational Safety and Health
could contribute as well. The NTP already
publishes all of its data and methods in its
reports; however, it does not publish raw data
or studies with nonstandard protocols online.
In any case, busy investigators may oppose this
not only because of the effort and resources
required but also because they would be relin
quishing exclusive access to their own raw data
(and therefore the risk of being “scooped”) for
the possibility of future requests for reanalysis.
Even in cases where investigators contemplate
no further data analyses, they may have con
cerns about the effort to respond to questions
about repeat analyses. In any case, additional
resources would be required, and this is not
a time of plenty for research in the United
States or anywhere else. In short, as in all of
life, there is no free lunch. We already have
mechanisms for disclosure of data used by the
U.S. EPA in decision making and even for
obtaining raw data. It is doubtful that we can
afford the luxury of having this information
available for release prior to any request, and it
is uncertain who should be responsible for the
cost and effort required to provide it.
We conclude that, as is the case for clinical
trials, a registry for studies that could handle
a wide variety of methodologies and methods
of analysis and provide a more complete and
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standardized presentation of statistical results
and other parameters than is possible in the
peer-reviewed literature would be a tremendous
resource to society for increasing transparency
and improving assessments of pesticides and
chemicals. However, at present, there is no
evidence that there is a net social benefit to
requiring collection of and access to raw data
for all studies utilized by the U.S. EPA prior
to requests for such data from interested
parties. As a first step the U.S. EPA, NTP,
and NLM should begin to generate discussions
among agencies and with interested outside
parties, including academic researchers and the
regulated industry, on the possible creation of
a reporting system for environmental health
studies of chemicals and pesticides that would
systematically collect results and data about
studies—but not raw data.
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